Market
Progress

Home

Clinical Testing

Market Progress

Publications

Blog

Leadership

CereFast Market Strategy

Donec condimentum diam sed metus luctus, ac interdum dolor finibus.
Mauris tempor lacus porta tempus convallis.
Aliquam condimentum ante vitae porta auctor.
Donec vel ipsum sed libero vehicula pulvinar ac in dolor.
Vestibulum et lectus malesuada, commodo arcu sit amet, facilisis quam.
Nam gravida urna a elit sagittis, ut convallis eros condimentum.

ambulance-cerefast-use


Market	Intensive Care Unit	Emergency Departments	Ambulances
Indication	Vasospasm	Ischemic Stroke	Ischemic Stroke
Annual Patients	21,000 (U.S.)	8000,000 (Stroke / U.s.) 1,100,000 (Stroke / E.U.)	8000,000 (Stroke / U.s.) 1,100,000 (Stroke / E.U.)
Facilities (U.S.)	450 Hospitals	16,500 Hospitals	158,000 Ambulances
Customer	Neurosurgery Departments	Emergency Medical Departments	Ambulance Owners / Operators / Manufacturers
Regulatory Pathway	Humanitarian Device Exemption	Expedited Access PMA ( Class IIa in E.U.)	Expedited Access PMA ( Class IIa in E.U.)

Learn More and Contact Us

Leadership

Disclaimer: 1c0, emergency department, or amourance “CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.”